| REVIEW ARTICLE |
|
| Year : 2007 | Volume
: 23
| Issue : 2 | Page : 97-108 |
|
|
Premature ejaculation
Chris G McMahon
Australian Centre For Sexual Health Suite 2-4, Berry Road Medical Centre 1a Berry Rd St. Leonards, Australia
Correspondence Address:
Chris G McMahon
Australian Centre For Sexual Health Suite 2-4, Berry Road Medical Centre 1a Berry Rd St Leonards
Australia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0970-1591.32056
|
|
|
Premature ejaculation (PE) is a common male sexual disorder. Recent normative data suggests that men with an intravaginal ejaculatory latency time (IELT) of less than 1 minute have "definite" PE, while men with IELTs between 1 and 1.5 minutes have "probable" PE. Although there is insufficient empirical evidence to identify the etiology of PE, there is limited correlational evidence to suggest that men with PE have high levels of sexual anxiety and inherited altered sensitivity of central 5-HT (5-hydroxytryptamine, serotonin) receptors. Pharmacological modulation of the ejaculatory threshold using off-label daily or on-demand selective serotonin re-uptake inhibitors is well tolerated and offers patients a high likelihood of achieving improved ejaculatory control within a few days of initiating treatment, consequential improvements in sexual desire and other sexual domains. Investigational drugs such as the ejaculo-selective serotonin transport inhibitor, dapoxetine represent a major development in sexual medicine. These drugs offer patients the convenience of on-demand dosing, significant improvements in IELT, ejaculatory control and sexual satisfaction with minimal adverse effects. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
